[{"id":"6ad48fdc-0f2c-4ee1-985e-f1329da636f0","acronym":"SYTHROM","url":"https://clinicaltrials.gov/study/NCT04539678","created_at":"2021-01-21T20:53:00.583Z","updated_at":"2025-02-25T13:40:13.722Z","phase":"","brief_title":"SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications","source_id_and_acronym":"NCT04539678 - SYTHROM","lead_sponsor":"Nantes University Hospital","biomarkers":" CALR","pipe":"","alterations":" ","tags":["CALR"],"overall_status":"Completed","enrollment":" Enrollment 253","initiation":"Initiation: 05/21/2019","start_date":" 05/21/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-02-21"},{"id":"5202b47d-cbbb-4824-a53c-3a13ffa0fe0a","acronym":"LIMBER","url":"https://clinicaltrials.gov/study/NCT05936359","created_at":"2023-07-07T14:09:44.600Z","updated_at":"2025-02-25T14:42:12.068Z","phase":"Phase 1","brief_title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","source_id_and_acronym":"NCT05936359 - LIMBER","lead_sponsor":"Incyte Corporation","biomarkers":" CALR","pipe":"","alterations":" ","tags":["CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2025-02-14"},{"id":"70692651-6672-45ae-886f-cba93081de75","acronym":"LIMBER","url":"https://clinicaltrials.gov/study/NCT06034002","created_at":"2023-09-13T15:10:28.189Z","updated_at":"2025-02-25T14:42:20.629Z","phase":"Phase 1","brief_title":"A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms","source_id_and_acronym":"NCT06034002 - LIMBER","lead_sponsor":"Incyte Corporation","biomarkers":" CALR","pipe":"","alterations":" ","tags":["CALR"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/04/2023","start_date":" 12/04/2023","primary_txt":" Primary completion: 10/29/2028","primary_completion_date":" 10/29/2028","study_txt":" Completion: 10/29/2028","study_completion_date":" 10/29/2028","last_update_posted":"2025-02-14"},{"id":"1f02bb00-f1cc-41ae-861d-71bd39144975","acronym":"VYP","url":"https://clinicaltrials.gov/study/NCT06715267","created_at":"2025-02-26T10:35:18.326Z","updated_at":"2025-02-26T10:35:18.326Z","phase":"","brief_title":"Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)","source_id_and_acronym":"NCT06715267 - VYP","lead_sponsor":"University Hospital, Brest","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" CALR mutation","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CALR mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 04/01/2038","primary_completion_date":" 04/01/2038","study_txt":" Completion: 04/01/2038","study_completion_date":" 04/01/2038","last_update_posted":"2024-12-04"},{"id":"8873703a-abd3-465c-96d4-165ce40e19a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04226950","created_at":"2021-01-18T20:33:33.025Z","updated_at":"2024-07-02T16:35:07.209Z","phase":"Phase 2","brief_title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia","source_id_and_acronym":"NCT04226950","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 11/20/2024","study_completion_date":" 11/20/2024","last_update_posted":"2024-04-29"},{"id":"e36ce158-5d2c-43a5-8d9f-4bf96a854310","acronym":"ALLO-BAT","url":"https://clinicaltrials.gov/study/NCT04217356","created_at":"2021-01-18T20:31:57.752Z","updated_at":"2024-07-02T16:35:13.310Z","phase":"","brief_title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","source_id_and_acronym":"NCT04217356 - ALLO-BAT","lead_sponsor":"University Health Network, Toronto","biomarkers":" TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR","pipe":" | ","alterations":" TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation","tags":["TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • hydroxyurea"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/05/2020","start_date":" 08/05/2020","primary_txt":" Primary completion: 08/05/2025","primary_completion_date":" 08/05/2025","study_txt":" Completion: 02/05/2026","study_completion_date":" 02/05/2026","last_update_posted":"2024-03-22"},{"id":"6dcd86de-9151-4b21-9983-a57a1be5a9d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05025488","created_at":"2021-08-27T12:53:08.421Z","updated_at":"2024-07-02T16:35:14.494Z","phase":"Phase 1","brief_title":"Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm","source_id_and_acronym":"NCT05025488","lead_sponsor":"Marina Kremyanskaya","biomarkers":" CALR","pipe":" | ","alterations":" CALR mutation","tags":["CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/04/2023","start_date":" 04/04/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-15"},{"id":"58702155-c7f5-4adb-9515-8aecf200fa86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620681","created_at":"2021-01-19T20:34:25.590Z","updated_at":"2024-07-02T16:35:20.265Z","phase":"Phase 1/2","brief_title":"CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML","source_id_and_acronym":"NCT04620681","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)","tags":["JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2024-02-08"},{"id":"e1c26bff-16d7-4b47-8bbc-7cfb19350620","acronym":"","url":"https://clinicaltrials.gov/study/NCT03566446","created_at":"2021-01-21T20:52:51.690Z","updated_at":"2024-07-02T16:35:43.105Z","phase":"Phase 1","brief_title":"CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms","source_id_and_acronym":"NCT03566446","lead_sponsor":"Inge Marie Svane","biomarkers":" CALR","pipe":" | ","alterations":" CALR mutation","tags":["CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CALR mutation"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 02/20/2020","primary_completion_date":" 02/20/2020","study_txt":" Completion: 04/30/2021","study_completion_date":" 04/30/2021","last_update_posted":"2023-07-13"},{"id":"25d552ed-ce76-45f4-8458-43b28986379b","acronym":"CALRSUIVI","url":"https://clinicaltrials.gov/study/NCT04942080","created_at":"2021-06-28T17:52:41.223Z","updated_at":"2024-07-02T16:36:01.159Z","phase":"","brief_title":"Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)","source_id_and_acronym":"NCT04942080 - CALRSUIVI","lead_sponsor":"University Hospital, Angers","biomarkers":" CALR","pipe":"","alterations":" ","tags":["CALR"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 10/28/2021","start_date":" 10/28/2021","primary_txt":" Primary completion: 04/28/2023","primary_completion_date":" 04/28/2023","study_txt":" Completion: 04/28/2026","study_completion_date":" 04/28/2026","last_update_posted":"2022-11-03"},{"id":"4e6ac4ec-251c-4f76-b6c7-5db34e645505","acronym":"BioPredictor","url":"https://clinicaltrials.gov/study/NCT05440838","created_at":"2022-07-01T21:55:24.459Z","updated_at":"2024-07-02T16:36:07.924Z","phase":"","brief_title":"Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.","source_id_and_acronym":"NCT05440838 - BioPredictor","lead_sponsor":"University Hospital, Angers","biomarkers":" JAK2 • CALR","pipe":"","alterations":" ","tags":["JAK2 • CALR"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/08/2022","start_date":" 09/08/2022","primary_txt":" Primary completion: 09/07/2024","primary_completion_date":" 09/07/2024","study_txt":" Completion: 10/04/2029","study_completion_date":" 10/04/2029","last_update_posted":"2022-07-01"},{"id":"8e772c5c-efa1-43b0-a436-6535ec330b7b","acronym":"PMF/ET-FLT","url":"https://clinicaltrials.gov/study/NCT03116542","created_at":"2021-01-18T15:21:18.891Z","updated_at":"2024-07-02T16:36:40.562Z","phase":"","brief_title":"18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia","source_id_and_acronym":"NCT03116542 - PMF/ET-FLT","lead_sponsor":"Hamad Medical Corporation","biomarkers":" IDH1 • IDH2 • JAK2 • SF3B1 • ASXL1 • TET2 • SRSF2 • CALR","pipe":"","alterations":" ","tags":["IDH1 • IDH2 • JAK2 • SF3B1 • ASXL1 • TET2 • SRSF2 • CALR"],"overall_status":"Unknown status","enrollment":" Enrollment 21","initiation":"Initiation: 05/07/2017","start_date":" 05/07/2017","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2020-09-29"},{"id":"bb338bc0-84a5-416d-9940-f963dcb3cec6","acronym":"FAST","url":"https://clinicaltrials.gov/study/NCT02611973","created_at":"2021-01-18T12:41:23.906Z","updated_at":"2024-07-02T16:37:19.528Z","phase":"Phase 3","brief_title":"Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia","source_id_and_acronym":"NCT02611973 - FAST","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F • CALR mutation","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxyurea • aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 2250","initiation":"Initiation: 03/10/2016","start_date":" 03/10/2016","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2017-07-26"},{"id":"4debac25-5f39-463e-8915-abc74602ad24","acronym":"","url":"https://clinicaltrials.gov/study/NCT01259817","created_at":"2021-01-18T05:04:55.274Z","updated_at":"2024-07-02T16:37:26.611Z","phase":"Phase 2","brief_title":"Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)","source_id_and_acronym":"NCT01259817","lead_sponsor":"Ronald Hoffman","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 135","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-01-11"},{"id":"93e3d1e1-725a-4189-96aa-f8051ef2aad9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02528877","created_at":"2021-01-18T12:13:38.737Z","updated_at":"2024-07-02T16:37:29.133Z","phase":"Phase 1","brief_title":"Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis","source_id_and_acronym":"NCT02528877","lead_sponsor":"City of Hope Medical Center","biomarkers":" JAK2 • CALR","pipe":"","alterations":" ","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • sirolimus • melphalan • fludarabine IV"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2016-09-14"}]